C1 esterase inhibitor

Compound Name:C1 esterase inhibitorMolecular Target:C1r and C1s of the classical complement pathways, MASP-1 and MASP-2 of the MBL complement pathway, kallikrein, factors Xia and XIIaMolecular Structure:Purified physiological proteinLicensed Indication:Hereditary angioneurotic edemaManufacturer and/or Distributor:Sanquin/ViroPharmaInitial FDA Approval2008SummaryC1 esterase inhibitor (C1-INH) concentrates are effective for the treatment of attacks (on-demand treatment) and the prophylaxis (short- and long-term) of hereditary angioedema (HAE). Patients with HAE lack functional C1-INH, resulting in excessive activation of the complement system (with resulting reduced C4 serum levels), as well as overproduction of bradykinin (responsible for the capillary permeability and angioedema). Replacement with exogenous C1-INH restores normal C1-INH functional activity. Two C1-INH concentrates are derived from human plasma, following pasteurization and nanofiltration: Berinert and Cinryze. Berinert is approved in adults and children for the on-demand treatment of HAE attacks in Germany and Europe (since 1979), in the USA (since 2009), and in Canada (since 2010). Berinert is licensed for self-administration intravenously at home. Cinryze is approved in adults and adolescents for the on-demand treatment and prophylaxis (short- and long-term) of HAE attacks in Germany and Europe (since 2011), although in the USA, it is approved for the long-term prophylaxis of HAE attacks (since 2008). Cinryze is self-administered intravenously every 3-4 days. Of note, Cetor is a similar product, approved in the European Union for acute attacks, but is not approved by the FDA in the U.S. One recombinant C1-INH is currently available: Ruconest (previously, Rhucin). The product is obtained from the milk of transgenic rabbits (i.e. the human C1INH gene is introduced into fertilized rabbit oocytes in a mammary-gland-specific expression vector). Ruconest is approved in adults and adolescents for the on-demand treatment of HAE attacks in Europe (since 2010) and USA (since 2014). It is self-administered intravenously. Significant safety concerns that have been reported include: (1) hypersensitivity reactions (including anaphylaxis); (2) thrombotic events (arterial and venous). (3) Others: headache, nausea, diarrhea. As this is a blood product, there is also the theoretical risk of transmission of an infectious agent.References

Package Inserts:

1. Lunn M, Santos C, Craig T. Cinryze as the first approved C1 inhibitor in the USA for the treatment of hereditary angioedema: approval, efficacy and safety. J Blood Med. 2010;1:163-170. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=22282695

2. Lyseng-Williamson KA. Nanofiltered human C1 inhibitor concentrate (Cinryze(R)): in hereditary angioedema. BioDrugs. 2011 Oct 1;25(5):317-327. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21942916

3. Parikh N, Riedl MA. New therapeutics in C1INH deficiency: a review of recent studies and advances. Curr Allergy Asthma Rep. 2011 Aug;11(4):300-308. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21607669

4. Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010 Aug 5;363(6):513-522. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20818886

5. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med. 2008 Sep 4;359(10):1027-1036. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18768946

6. Davis AE, 3rd. Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol. 2008 Jan;100(1 Suppl 2):S7-12. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18220146

7. Cicardi M, Zingale LC. The deficiency of C1 inhibitor and its treatment. Immunobiology. 2007;212(4-5):325-331. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17544817

8. Tilles S, Borish L, Cohen J. Management of hereditary angioedema in 2012: scientific and pharmacoeconomic perspectives. Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology. 2013;110(2):70-74. http://dx.doi.org/10.1016/j.anai.2012.11.014

9. Lang DM, Aberer W, Bernstein JA, Chng HH, Grumach AS, Hide M, Maurer M, Weber R, Zuraw B. International consensus on hereditary and acquired angioedema. Ann Allergy Asthma Immunol. 2012 Dec;109(6):395-402.

10. Bork K. An evidence based therapeutic approach to hereditary and acquired angioedema. Curr Opin Allergy Clin Immunol. 2014 Aug;14(4):354-62.